Simulect
Simulect ingredients
| Active ingredient | Strength |
|---|---|
| Basiliximab | 10 mg/2.5mL, 20 mg/5mL |
What Simulect is used for
The FDA lists the approved uses on the official label (below). In the EU, basiliximab is approved as Simulect for:
Simulect is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation in adult and paediatric patients (1-17 years). It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Simulect
- Generic name
- Basiliximab
- Made by
- Novartis Pharmaceuticals Corporation
- Forms
- Injection, Powder, For Solution
- Given
- Intravenous
- Drug class
- Interleukin-2 Receptor Blocking Antibody
- FDA approval
- Biologic licence (BLA) BLA103764
- On the US market since
- 1998
Official information
- MedlinePlus drug information (search for Basiliximab)
In India
- Basiliximab: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Simulect?
Simulect (Basiliximab) is a specialist medicine made by Novartis Pharmaceuticals Corporation, approved by the US FDA.
What are the ingredients of Simulect?
Simulect contains Basiliximab (10 mg/2.5mL, 20 mg/5mL).
Is Simulect approved in Europe?
The same active substance is approved in the EU as Simulect.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA